A0469 - Peripheral Immune Markers Can Detect Hepatocellular Carcinoma in Blood in a Latin American Cohort

Jose D. Debes, MD, PhD¹, Angelo Mattos, MD, PhD², Jhon Prieto, MD³, Enrique Carrera, MD⁴, Melina Ferreiro, MD⁵, Domingo Balderramo, MD⁶, Maria Masotti, PhD¹, Joe Koopmeiners, PhD¹, Marco Arrese, MD⁷, Javier Diaz Ferrer, MD⁸, Andre Boonstra, PhD^9
1University of Minnesota, Minneapolis, MN; ²Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; ³Cehyd, Bogota, Amazonas, Colombia; ⁴Universidad San Francisco de Quito, Quito, Pichincha, Ecuador; ⁵Hospital Clinicas, Buenos Aires, Buenos Aires, Argentina; ⁶Hospital Privado Universitario de Córdoba, Cordoba, Cordoba, Argentina; ⁷Pontificia Universidad Católica de Chile, Santiago, Region Metropolitana, Chile; ⁸Hospital Nacional Edgardo Rebagliati Martins, Lima, Lima, Peru; ⁹Erasmus University Rotterdam, Rotterdam, Zuid-Holland, Netherlands

Introduction: Late detection of hepatocellular carcinoma (HCC) due to suboptimal surveillance with ultrasound is a major problem worldwide but with further importance in resource-limited settings. Blood biomarkers are urgently needed and currently alpha-fetoprotein (AFP) is the only accepted biomarker. However, AFP has poor accuracy for early HCC detection and has mainly been studied in resource-rich settings. We prospectively investigated circulating immune markers to detect HCC in 2 different groups of Latin American patients acting as discovery and validation cohorts.

Methods: Through the ESCALON network we prospectively evaluated a discovery cohort of 127 individuals with HCC and 113 cirrhotic controls from 3 countries in Latin America (Argentina, Brazil and Ecuador) as well as a validation cohort of 145 HCCs and 75 cirrhotic individuals from a different set of institutions in Latin America (Chile, Peru, Argentina, Ecuador, Colombia). Blood samples were analyzed for 37 unique immune markers using the multiplex Bio-Rad platform. Differences between HCC and cirrhosis were analyzed via t-test and ANOVA, and tuned with lasso coefficient-bootstrap computing. We used leave-one-out cross-validation (LOOCV) to compute an ROC curve.



Results: In the discovery cohort 22 markers showed a significant difference between cases and controls for all size tumors and 15 for those tumors < 5cm. A set of 5 markers which were highly differential in HCC vs cirrhosis controls identified via Lasso and bootstrap: HGF, MIP-3a, MIG, CCL-25, and MDC. The AUROC for this top-5 set in detecting HCC was 0.83 (CI 0.78-0.88) for all tumors and 0.75 (CI 0.66-0.83) for tumors < 5cm. In this same cohort, the AUROC for AFP was only 0.69 for all tumors and 0.66 for tumors < 5cm. The addition of AFP to the top-5 markers did not significantly increase the AUROC (0.83 to 0.85). We investigated the set of top-5 markers in the validation cohort and found that they could detect HCC with an AUROC of 0.73 (CI 0.642-0.810). The main differences between both cohorts were in the underlying liver diseases in HCC, with viral hepatitis being the most common in the validation cohort (42%) and non-alcoholic fatty liver disease in the validation cohort (56%).

Discussion: Our study identified a set of 5 cytokines that can detect HCC by means of blood measurement in a discovery and validation cohort in Latin America. To our knowledge this is the first study assessing immune markers with a high degree of accuracy in a unique Latin American cohort.


Disclosures:


Jose D. Debes, MD, PhD¹, Angelo Mattos, MD, PhD², Jhon Prieto, MD³, Enrique Carrera, MD⁴, Melina Ferreiro, MD⁵, Domingo Balderramo, MD⁶, Maria Masotti, PhD¹, Joe Koopmeiners, PhD¹, Marco Arrese, MD⁷, Javier Diaz Ferrer, MD⁸, Andre Boonstra, PhD⁹. A0469 - Peripheral Immune Markers Can Detect Hepatocellular Carcinoma in Blood in a Latin American Cohort, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.